Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
- PMID: 33438566
- DOI: 10.2174/1871520621666210112113852
Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Abstract
Background: Anlotinib is a multi-target tyrosine kinase inhibitor that has been reported to have activity against colorectal cancer. However, the mechanisms of how anlotinib mediates drug-resistance of colorectal cancer have not been fully described. Particularly the potential mechanisms regarding the inhibition of proliferation and induction of apoptosis remain unknown.
Objective: In this study, we intended to study the effect and related-mechanism of the proliferation, migration, invasion and induced apoptosis of anlotinib overcoming multidrug resistant colorectal cancer cells through in vitro experiments.
Methods: Cell viability was determined by MTT assays and the resistant index was calculated. Colony formation and PI/RNase Staining were used for testing the proliferation of resistant cells. DAPI staining and Annexin V-FITC/PI staining were used to detect cell apoptosis. Migration and invasion were examined by transwell. Protein expression and activation of PI3K/AKT pathway were detected by western blot. LY294002 was used to verify whether anlotinib overcomes the drug-resistance of CRC cells by inactivating the PI3K/AKT pathway.
Results: The results showed that the HCT-8/5-FU cells were resistant to multiple chemotherapy drugs (5-FU, ADM and DDP). Anlotinib significantly inhibited cell viability, proliferation, migration, invasion and induced cell apoptosis. Moreover, anlotinib down-regulated the expression of survivin, cyclin D1, CDK4, caspase-3, Bcl-2, MMP-2, MMP-9, vimentin and N-cadherin, but up-regulated cleaved-caspase-3, Bax and E-cadherin and blocked the activity of the PI3K/AKT in HCT-8/5-FU cells. We found anlotinib and LY294002 overcame the drug resistance of HCT-8/5-FU cells by reducing the expression of PI3K/p-AKT.
Conclusion: Anlotinib inhibited the proliferation, migration, invasion and induced apoptosis of HCT-8/5-FU cells, and the mechanisms may be that anlotinib conquered multidrug resistance of colorectal cancer cells via inactivating of PI3K/AKT pathway.
Keywords: Anlotinib; PI3K/AKT pathway.; apoptosis; colorectal cancer; invasion; migration; multiple drug resistance; proliferation.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
[Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway].Nan Fang Yi Ke Da Xue Xue Bao. 2024 Oct 20;44(10):1965-1975. doi: 10.12122/j.issn.1673-4254.2024.10.15. Nan Fang Yi Ke Da Xue Xue Bao. 2024. PMID: 39523097 Free PMC article. Chinese.
-
Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2331-2343. doi: 10.26355/eurrev_202103_25272. Eur Rev Med Pharmacol Sci. 2021. PMID: 33755971
-
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.Cell Death Dis. 2020 Jul 24;11(7):573. doi: 10.1038/s41419-020-02749-7. Cell Death Dis. 2020. PMID: 32709873 Free PMC article.
-
The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions.Exp Mol Pathol. 2022 Aug;127:104787. doi: 10.1016/j.yexmp.2022.104787. Epub 2022 May 27. Exp Mol Pathol. 2022. PMID: 35644245 Review.
-
Cell survival and metastasis regulation by Akt signaling in colorectal cancer.Cell Signal. 2013 Aug;25(8):1711-9. doi: 10.1016/j.cellsig.2013.03.025. Epub 2013 Apr 18. Cell Signal. 2013. PMID: 23603750 Free PMC article. Review.
Cited by
-
Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.Ann Transl Med. 2022 Mar;10(6):294. doi: 10.21037/atm-22-544. Ann Transl Med. 2022. PMID: 35433955 Free PMC article.
-
Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer.Front Endocrinol (Lausanne). 2023 Oct 10;14:1242991. doi: 10.3389/fendo.2023.1242991. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37881499 Free PMC article. Review.
-
Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism.Ann Transl Med. 2022 Dec;10(24):1337. doi: 10.21037/atm-22-5438. Ann Transl Med. 2022. PMID: 36660682 Free PMC article.
-
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.Arch Virol. 2021 Mar;166(3):675-696. doi: 10.1007/s00705-021-04958-7. Epub 2021 Jan 18. Arch Virol. 2021. PMID: 33462671 Free PMC article. Review.
-
Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.Can Respir J. 2024 Mar 4;2024:2632014. doi: 10.1155/2024/2632014. eCollection 2024. Can Respir J. 2024. PMID: 38468814 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous